Apellis Pharmaceuticals宣布与Sobi达成一项有上限的版税购买协议，根据该协议，Apellis将获得高达3亿美元的Apellis未来Aspaveli在美国以外地区的版税的90%（系统性Pegcetacoplan）

2025-07-01 19:09

Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI.
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN
Non-dilutive financing further strengthens Apellis' balance sheet
Apellis retains full U.S. commercialization rights for systemic pegcetacoplan
Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases